Previous 10 | Next 10 |
In less than two trading sessions, Compass Therapeutics (NASDAQ:CMPX) shares have risen ~40% thanks to insider purchases. SEC filings posted after Tuesday's closing bell reveal two large share purchases. CEO Thomas Schuetz picked up 27,836 shares on May 10 and now owns ...
Gainers: Lordstown Motors RIDE +45%. Squarespace SQSP +43%. AppLovin APP +36%. Carvana CVNA +29%. MoneyLion ML +29%. SunOpta STKL +27%. Compass Therapeutics (CMPX) +25%. Bakkt Holdings BKKT +25%. Cullinan Oncology CGEM +25%. Losers: Atento ATTO -36...
Compass Therapeutics press release (NASDAQ:CMPX): Q1 GAAP EPS of -$0.07 beats by $0.06. As of March 31, 2022, cash and cash equivalents were $136.4 million as compared to $39.7 million as of March 31, 2021 Shares -5.92% PM. For further details see: Compass Therapeutics GAAP EPS of -$0.0...
The FDA cleared the investigational new drug application for CTX-009 (DLL4 X VEGF-A bispecific) in January allowing the Company to expand the ongoing Phase 2 study in patients with biliary tract cancer (BTC) to a global study and initiate dosing patients in the United States in early Q3...
BOSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced Thomas J. Schuetz, M.D., Ph.D., Co-founder, and Chief Executive Officer is prese...
CTX-009 Demonstrated a 42% Overall Response Rate (ORR) Based on 10 Partial Responses (PRs) in 24 Enrolled Patients CTX-009 Continues to be Well Tolerated, Consistent with the Phase 1 Studies Compass Plans to Initiate Stage 2 of the Phase 2 Study in the U.S. i...
Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET Key Opinion Leader to Participate BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat ca...
BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today is pleased to announce the appointment of two new dir...
Gainers: Lixte Biotechnology Holdings (LIXT) +205%. PolarityTE (PTE) +96%. Biodesix (BDSX) +29%. MiNK Therapeutics (INKT) +27%. Enservco (ENSV) +25%. Actinium Pharmaceuticals (ATNM) +21%. Compass Therapeutics (CMPX) +21%. Sunshine Biopharma (SBFM) +22%. Singularity Future Technology (SGLY) +2...
BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage oncology focused biotechnology company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported new preclinical data on CTX-8371, a next generati...
News, Short Squeeze, Breakout and More Instantly...
Compass Therapeutics Inc. Company Name:
CMPX Stock Symbol:
OTCMKTS Market:
Compass Therapeutics Inc. Website:
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside cha...
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Sc...
CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic or locally advanced malignancies who had progressed on approved PD-1 or PD-L1 inhibitors....